Abbott Laboratories (FreeStyle Libre) (ABT) is a publicly traded Connected Wearables company founded in 1888 and based in Abbott Park, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.

Abbott's TactiFlex Duo catheter combining PFA and RF energy shows sustained efficacy at one year in complex atrial fibrillation cases, supporting an FDA submission.

Abbott wins CE mark for a new left atrial appendage closure device, competing with Boston Scientific in the stroke-prevention market.

Abbott receives FDA clearance for the Libre Duo 10 Day, a sensor that measures both glucose and ketones.

Stryker, Medtronic, and Abbott are among medtech firms that have disclosed cyberattacks so far in 2026.
A continuous glucose monitoring (CGM) system that provides real-time glucose readings every minute via a small sensor worn on the back of the upper arm for up to 14 days. Designed for people with diabetes, it eliminates the need for routine fingerstick calibration and transmits glucose data directly to a smartphone app. It is the smallest and thinnest CGM sensor available, featuring optional real-time alerts for high and low glucose levels.
An enhanced version of the FreeStyle Libre 3 CGM sensor offering extended wear of up to 15 days with real-time glucose readings every minute. It is authorized for use with compatible automated insulin delivery (AID) systems, giving people with diabetes tighter glucose control. The sensor pairs with the Libre mobile app for convenient, scan-free glucose monitoring and trend analysis.
A flash glucose monitoring system that measures glucose levels through a small sensor worn on the upper arm for up to 14 days. Users can scan the sensor with a reader or smartphone to see a real-time glucose reading, an 8-hour history, and a trend arrow. It features optional real-time alarms for low and high glucose, helping people with diabetes manage their condition without routine fingerstick calibration.